List of Antibody Drug Conjugates Companies in Italy - 3

Lead Discovery Siena - LDS - is an innovative SME focused on the research for new drugs. LDS offers pharmaceutical services for Industry and Academia and has a diversified pipeline of in licensed and proprietary products for oncology and infections therapeutic areas, including rare diseases. LDS was founded as a spin-off of the University of Siena in 2012 by combining the scientific background and the entrepreneurship of its management to offer specific competences and solutions in drug discovery. LDS capitalizes on the wide scientific expertise in pharmacology and medicinal chemistry to efficiently expedite the discovery and development of small molecule medicines. A number of molecules have been successfully advanced by LDS team as evidenced by publications and patents, and several goals achieved in the course of collaborations which earned us the trust of our customers. LDS actively participates to national and international projects, with a special attention to local synergies at industrial and academic level within the Life Science area. LDS laboratories are located in the Toscana Life Sciences facilities (www.toscanalifesciences.org), a non-profit organization supporting research activities and promoting the creation of innovative companies in Life Sciences.

MediaPharma Srl is a preclinical stage biotech company focusing on research and development of monoclonal antibodies, Antibody-Drug Conjugates (ADCs) and other products for the treatment of cancer and other severe diseases with high unmet medical needs. At MediaPharma, scientists, doctors and entrepreneurs share the same values and have been working together for years.

Nerviano Medical Sciences S.r.l. (NMS Srl) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.  NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. Our capabilities are extended by NMS Group affiliates Accelera (AdMet) and NerPharMa (manufacturing), covering the entire drug development process. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including with encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production. Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets.